Demonstrates improved detection of CD8+ T cells in biosensors, suggesting enhanced clinical applications.
A novel electrochemical biosensor was developed for accurate and sensitive detection of CD8+ T cells, as a key biomarker in clinical and immunological analysis. A screen-printed electrode was modified through 20 cycles of electrodeposition using two approaches: a reduced graphene oxide–polypyrrole composite (A20) and graphene oxide reduced under UV irradiation during polymerization (B20). Characterization analysis indicated that A20 exhibited improved structural uniformity and a higher relative abundance of carboxyl groups compared to B20 sample. These features achieved through a simple and cost-effective fabrication process, significantly improved the electrochemical performance of A20, making it as an optimal sensing platform. The A20-based biosensor detected CD8+ T cells with limit of detection 1.19 × 104 cells.mL-1, which the results aligned with flow cytometry by 97%, confirming its precise accuracy. Further experiments using CD20+, CD19+ and CD4+ cells confirmed the biosensor’s selectivity. This study introduces a simple, scalable process for creating composites that greatly enhances the sensitivity of biosensors. Because it is affordable and easy to produce, this biosensor is well-suited for clinical and laboratory use, and also creates opportunities for developing sensors that detect other cellular biomarkers.
No takes yet. Share an insight, caveat, or question.
Amoo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: